Skip to main content

Drug Safety

RheumNow Podcast square
Dr. Jack Cush reviews and highlights his favorite abstracts and presentations from last week's virtual EULAR 2021 meeting. COSMOS: Guselkumab in TNF-IR PsA. # OP0230m Coates LC, et al. C-OPTIMISE:…
Video: The PsA SpA Paradox of Choice

Dr. Rachel Tate ( @uptoTate) reviews Dr. Laura Coates' presentation Personalized T

Dr. John Cush RheumNow

1 week ago
Video: The PsA SpA Paradox of Choice Dr. Rachel Tate ( @uptoTate) reviews Dr. Laura Coates' presentation Personalized Treatment Strategies in Psoriatic Arthritis, given at the virtual #EULAR2021 meeting. https://t.co/Yg12SHR1MF https://t.co/UiCYDU5XGc
meeting.audience.3.jpg
Lots of presentations on the last day; notably, the late breaking abstracts and others. Here are a few of my favorites from Day 4. Mavrilimumab in COVID-19: LB0001– Mavrilimumab, (MAV) a human anti…
DPGN, lupus, nephritis, GN, glomerulonephritis, biopsy, kidney
Combination disease modifying antirheumatic drug (DMARD) therapy may not be only for rheumatoid arthritis; combining disease modifying agents may be the path to better renal response.  Professor …
PSA068.jpg
Dr. Philip Mease et al presented results of a phase II trial (OP0227) at EULAR 2021 that shows the efficacy and safety of an oral tyrosine kinase inhibitor (TYKi), deucravacitinib, for treatment of…
yes, no, maybe
Multiple studies compared effectiveness, retention and/or safety of biological DMARDs (bDMARDs) and JAK inhibitors (JAKi) at EULAR 2021. But be careful of what you read because depending on age,…
×